• Oncology Conference Insight: ASH 2016 --- Immunotherapies such as checkpoint inhibitors have had a dramatic impact on treatment paradigms for many tumor types over the past few years, and their full potential is far from being realized. Hot on the heels of checkpoint inhibitors are engineered, adoptive T-cell therapies that represent another promising advancement.
  • GALLIUM turns Gazyva into gold in NHL

    by Jay Grisolano  |  Dec 5, 2016
    Oncology Conference Insight: ASH 2016 --- In the management of non-Hodgkin lymphoma (NHL), Rituxan-based therapy forms the foundation for therapy in all settings. This holds true for most subtypes of NHL, including follicular lymphoma, mantle cell lymphoma, and diffuse B-cell lymphoma. While Rituxan-based therapy is highly effective and leads to improvement in survival rates, patients are rarely cured, and relapse is common, occurring in about 20-30% of patients.
  • On December 1, we mark World AIDS Day, which was created by WHO in partnership with the United Nations (UN) to raise awareness on disease prevention as well as fight the prejudice and stigmas that people living with HIV and AIDS have to cope with.
  • A lack of engagement after the patient leaves a doctor’s office or hospital contributes to higher costs and worse health outcomes. The easier we make it for patients to engage with their health the more likely they are to do so in a way that will make an actual difference.
  • Reach out to patients - we don't bite

    by Lynnette Cooke  |  Nov 18, 2016
    The gaps between patients, pharma, researchers and physicians offer an opportunity for the industry to step up and provide reliable, relatable information to empower consumers.